AR and neoplasm: pioneered this effort by subdividing TNBC into four subtypes—basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), and luminal androgen receptor (LAR)—based on gene expression profiles and the influence of tumor-infiltrating lymphocytes and tumor-associated stromal cells (2).